Latest News and Press Releases
Want to stay updated on the latest news?
-
SCHAUMBURG, Ill., March 5, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the approval and launch of Zoledronic Acid Injection 4 mg, the generic form of the...
-
Record Quarterly Revenue and Earnings Driven by New Product Launches Company Achieves Revised Fiscal Year 2012 Guidance SCHAUMBURG, Ill., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Sagent...
-
SCHAUMBURG, Ill., Jan. 31, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
-
SCHAUMBURG, Ill., Jan. 9, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced that due to the current critical shortage of Sodium Bicarbonate Injection, USP in the...
-
SCHAUMBURG, Ill., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today...
-
SCHAUMBURG, Ill., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
-
SCHAUMBURG, Ill., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Nafcillin for Injection, USP, in two vial presentations and one pharmacy...
-
SCHAUMBURG, Ill., Nov. 19, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
-
SCHAUMBURG, Ill., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Acetazolamide for Injection, USP, the generic form of the carbonic...
-
SCHAUMBURG, Ill., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced financial results for the quarter ended September 30, 2012. Third Quarter 2012...